Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast Cancer

Anna Kokot,Sachin Gadakh,Indrajit Saha,Ewa Gajda,Michał Łaźniewski,Somnath Rakshit,Kaustav Sengupta,Ayatullah Faruk Mollah,Michał Denkiewicz,Katarzyna Górczak,Jürgen Claesen,Tomasz Burzykowski,Dariusz Plewczynski

DOI: https://doi.org/10.3390/cimb46030171

2024-03-21

Current Issues in Molecular Biology

Abstract:HER2-positive breast cancer is one of the most prevalent forms of cancer among women worldwide. Generally, the molecular characteristics of this breast cancer include activation of human epidermal growth factor receptor-2 (HER2) and hormone receptor activation. HER2-positive is associated with a higher death rate, which led to the development of a monoclonal antibody called trastuzumab, specifically targeting HER2. The success rate of HER2-positive breast cancer treatment has been increased; however, drug resistance remains a challenge. This fact motivated us to explore the underlying molecular mechanisms of trastuzumab resistance. For this purpose, a two-fold approach was taken by considering well-known breast cancer cell lines SKBR3 and BT474. In the first fold, trastuzumab treatment doses were optimized separately for both cell lines. This was done based on the proliferation rate of cells in response to a wide variety of medication dosages. Thereafter, each cell line was cultivated with a steady dosage of herceptin for several months. During this period, six time points were selected for further in vitro analysis, ranging from the untreated cell line at the beginning to a fully resistant cell line at the end of the experiment. In the second fold, nucleic acids were extracted for further high throughput-based microarray experiments of gene and microRNA expression. Such expression data were further analyzed in order to infer the molecular mechanisms involved in the underlying development of trastuzumab resistance. In the list of differentially expressed genes and miRNAs, multiple genes (e.g., BIRC5, E2F1, TFRC, and USP1) and miRNAs (e.g., hsa miR 574 3p, hsa miR 4530, and hsa miR 197 3p) responsible for trastuzumab resistance were found. Downstream analysis showed that TFRC, E2F1, and USP1 were also targeted by hsa-miR-8485. Moreover, it indicated that miR-4701-5p was highly expressed as compared to TFRC in the SKBR3 cell line. These results unveil key genes and miRNAs as molecular regulators for trastuzumab resistance.

biochemistry & molecular biology

What problem does this paper attempt to address?

The paper aims to explore and reveal the molecular mechanisms of resistance to trastuzumab in HER2-positive breast cancer cells.

### Research Background and Objectives

- **Research Background**: HER2-positive breast cancer is a common type of cancer in women, characterized by HER2 receptor activation and hormone receptor activation. Although trastuzumab, a monoclonal antibody targeting HER2, has improved the treatment success rate of HER2-positive breast cancer, drug resistance remains a challenge.
- **Research Objectives**: By studying two breast cancer cell lines (SKBR3 and BT474), the potential molecular mechanisms of trastuzumab resistance are explored.

### Experimental Design and Methods

- **Experimental Design**: A two-stage approach was used for the study:
1. **Determine Optimal Drug Dose**: Based on cell proliferation rates, various doses of trastuzumab were optimized, and the optimal therapeutic dose for the two cell lines was determined.
2. **Culture Resistant Cell Lines**: Cells were continuously cultured for several months at the determined dose, with six time points selected for further analysis, from untreated cells to fully resistant cells.
- **Molecular Level Analysis**: Nucleic acids were extracted from the cells, and high-throughput microarray experiments of gene expression and microRNA (miRNA) expression were conducted to explore changes in molecular mechanisms.

### Main Findings

- **Key Genes and miRNAs**: The study identified several genes (such as BIRC5, E2F1, TFRC, and USP1) and miRNAs (such as hsa-miR-574-3p, hsa-miR-4530, and hsa-miR-197-3p) associated with trastuzumab resistance. These molecules were identified as key regulators of trastuzumab resistance.
- **Regulatory Network**: Downstream analysis showed that TFRC, E2F1, and USP1 are regulated by hsa-miR-8485, while miR-4701-5p is significantly higher expressed in the SKBR3 cell line than TFRC, revealing a complex regulatory network.

### Conclusion

This study reveals the key molecular players and pathways involved in trastuzumab resistance in HER2-positive breast cancer, providing valuable insights and potential therapeutic strategies to overcome this treatment challenge.